Ryan Gumpper

Mr. Ryan Gumpper


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2022 in Cell Reports
Verified
Journal Article
Open access
RGRyan Gumpper
Ryan Gumpper
JFJonathan F. Fay
Jonathan F. Fay
BRBryan L. Roth
Bryan L. Roth
RNA editing is a process by which post-transcriptional changes of mRNA nucleotides alter protein function through modification of the amino acid content. The 5HT2C serotonin receptor, which undergoes 32 distinct RNA-editing events leading to 24 protein isoforms, is a notable example of this process. These 5HT2C isoforms display differences in constitutive activity, agonist/inverse agonist potencies, and efficacies. To elucidate the molecular mechanisms responsible for these effects of RNA editing, we present four active-state 5HT2C-transducer-coupled structures of three representative isoforms (INI, VGV, and VSV) with the selective drug lorcaserin (Belviq) and the classic psychedelic psilocin. We also provide a comprehensive analysis of agonist activation and constitutive activity across all 24 protein isoforms. Collectively, these findings reveal a unique hydrogen-bonding network located on intracellular loop 2 that is subject to RNA editing, which differentially affects GPCR constitutive and agonist signaling activities.

19 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
RGRyan Gumpper
Ryan Gumpper
MJManish K. Jain
Manish K. Jain
KKKuglae Kim
Kuglae Kim
RSRenhong Sun
Renhong Sun
NSNing Sun
Ning Sun
BRBryan L. Roth
Bryan L. Roth
There is currently a resurgence in exploring the utility of classical psychedelics to treat depression, addiction, anxiety disorders, cluster headaches, and many other neuropsychiatric disorders. A biological target of these compounds, and a hypothesized target for their therapeutic actions, is the 5-HT2A serotonin receptor. Here, we present 7 cryo-EM structures covering all major compound classes of psychedelic and non-psychedelic agonists, including a β-arrestin-biased compound RS130-180. Identifying the molecular interactions between various psychedelics and the 5-HT2A receptor reveals both common and distinct motifs among the examined psychedelic chemotypes. These findings lead to a broader mechanistic understanding of 5-HT2A activation, which can catalyze the development of novel chemotypes with potential therapeutic utility and fewer side effects.

2 October 2024 in British Journal of Pharmacology
Verified
Journal Article
Closed access
RGRyan Gumpper
Ryan Gumpper
DNDavid E. Nichols
David E. Nichols

10 April 2026 in Science Advances
Verified
Journal Article
Open access
XLXiaoyi Li
Xiaoyi Li
DLDajiang Li
Dajiang Li
YTYuyang Tang
Yuyang Tang
MNMarie Nearing
Marie Nearing
BVBenjamin Varco-Merth
Benjamin Varco-Merth
GJGuochun Jiang
Guochun Jiang
The role of epigenetic regulation in HIV latency remains incompletely understood. We show that histone deacetylase 3 (HDAC3) inhibits trans-activator of transcription (Tat)-mediated HIV transcription through histone decrotonylation (HDCR), independent of deacetylase activity. Chemical biology approaches identified selective HDCR inhibitors (HDCRis) that reverse HIV latency with minimal impact on other histone acylations. Although HDAC2, HDAC3, and HDAC8 exhibit HDCR activity, genetic and chemical studies reveal that the HDCRi citarinostat is selective for HDAC3 and HDAC8. Molecular docking suggests that HDCRi binds outside the zinc-binding pocket, distinct from the classical HDAC inhibitor vorinostat (SAHA, suberoylanilide hydroxamic acid). Key residues (arginine-265, arginine-301, glutamine-113, and aspartic acid–57) are essential for HDCR selectivity, as their mutation abolishes HDCR activity and increases histone crotonylation without altering other acylation marks. Citarinostat increases histone crotonylation at the HIV long terminal repeat, robustly activating HIV transcription in cell lines, primary CD4 + T cells, and brain microglia from simian immunodeficiency virus–infected nonhuman primates and participants enrolled in the Last Gift rapid research autopsy cohort, highlighting HDCR as a promising therapeutic target for HIV latency.

3 December 2025 in Biochemistry
Verified
Journal Article
Closed access
MKMichael Bram Kuijer
Michael Bram Kuijer
CFCamryn J. Fulton
Camryn J. Fulton
TATalia L. Albert
Talia L. Albert
PKPaloma Knobloch
Paloma Knobloch
JWJing Wang
Jing Wang
BRBryan L. Roth
Bryan L. Roth

20 April 2026 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
YKYoojoong Kim
Yoojoong Kim
RGRyan Gumpper
Ryan Gumpper
YZYuxuan Zhuang
Yuxuan Zhuang
RDRon O. Dror
Ron O. Dror
BRBryan L. Roth
Bryan L. Roth
Bitter taste functions as a means of both protection against potentially toxic compounds and savoring bitter tasting foods and beverages. Among the 26 bitter taste receptors, taste receptor type 2 member 43 (TAS2R43) has been identified as key for recognizing the bitter taste of coffee. TAS2R43 has also been implicated in many other physiological processes, including the regulation of glucagon-like peptide 1 release from the intestine, bronchodilation, innate immunity and metabolism. Here we report cryo-electron microscopy structures of human TAS2R43 coupled with inhibitory G protein or gustducin (Ggust) stabilized by the potent nephrotoxin and carcinogen aristolochic acid I. Both structures revealed that aristolochic acid I binds in a presumed orthosteric pocket shared with other bitter taste receptor. Further structural, functional and computational studies revealed potential modes for coffee’s constituents including caffeine and cafestol, which are bitter tastants from coffee. Lastly, long-timescale molecular dynamics simulations identified potential cryptic allosteric pockets in TAS2R43. These structures could accelerate the search for specific bitter taste ligands that ultimately may be therapeutically useful.